Kalle Sigfridsson
Research Subjects
Research Interests
Kalle Sigfridsson has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Marie Strimfors
Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Gothenburg, S-413 83 Mölndal
7 shared publicationsLennart Lindfors
AstraZeneca R&D Gothenburg, S-431 83 Mölndal, Sweden
4 shared publicationsAixiang Xue
Animal Sciences and Technologies, Clinical Pharmacology and Safety Sciences, AstraZeneca , 35 Gatehouse Drive, Waltham, MA 02451
3 shared publicationsAnders J. Lundqvist
Discovery Drug Metabolism and Pharmacokinetics & Bioanalytical Chemistry, AstraZeneca R&D Mölndal, Mölndal, Sweden
3 shared publicationsAnna-Karin Granath
D Global Patient Safety, IMED Biotech Unit , AstraZeneca , Gothenburg , Sweden
3 shared publicationsLena Svensson
Bioscience Renal In Vivo Research and Early Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, 431 83 Gothenburg, Sweden
3 shared publications
Latest Publications
- 3 August 2026
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 78 (8)
Amorphous particles enhance oral exposure—a case study of a poorly soluble compound in preclinical, toxicology and early clinical studies
Objectives: The aim of this study was to investigate whether different liquid formulations of a selected candidate drug could be utilized to improve oral absorption and subsequent in vivo exposure. Methods: Polyethylene glycol 400 (PEG400) formulations with and without pH adjustment and hydroxypropyl-β-cyclodextrin (CD) formulations were prepared alongside amorphous and crystalline suspensions, the latter as micro- and nanocrystals. The suspensions of the compound were manufactured and evaluated for solubility, dissolution rate and in vivo exposure in rats, dogs, and humans, whereas the PEG400 and CD formulations were administered only to rats and/or dogs. Key findings: Amorphous microsuspensions of the active pharmaceutical ingredient (API) demonstrated the most promising in vivo results. CD formulation resulted in significantly lower drug exposure than expected. When amorphous suspensions were administered, an absorption difference was observed between male and female rats and a greater than dose linear increase in exposure was noted between two doses in humans. Conclusion: This study demonstrated that amorphous suspensions of a newly selected candidate drug resulted in superior oral absorption compared with more commonly used liquid formulations of the API in all investigated species. However, progressing with an amorphous form always carries inherent risks regarding chemical and physical stability.
- 3 August 2026
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 78 (8)
Amorphous particles enhance oral exposure—a case study of a poorly soluble compound in preclinical, toxicology and early clinical studies
Objectives: The aim of this study was to investigate whether different liquid formulations of a selected candidate drug could be utilized to improve oral absorption and subsequent in vivo exposure. Methods: Polyethylene glycol 400 (PEG400) formulations with and without pH adjustment and hydroxypropyl-β-cyclodextrin (CD) formulations were prepared alongside amorphous and crystalline suspensions, the latter as micro- and nanocrystals. The suspensions of the compound were manufactured and evaluated for solubility, dissolution rate and in vivo exposure in rats, dogs, and humans, whereas the PEG400 and CD formulations were administered only to rats and/or dogs. Key findings: Amorphous microsuspensions of the active pharmaceutical ingredient (API) demonstrated the most promising in vivo results. CD formulation resulted in significantly lower drug exposure than expected. When amorphous suspensions were administered, an absorption difference was observed between male and female rats and a greater than dose linear increase in exposure was noted between two doses in humans. Conclusion: This study demonstrated that amorphous suspensions of a newly selected candidate drug resulted in superior oral absorption compared with more commonly used liquid formulations of the API in all investigated species. However, progressing with an amorphous form always carries inherent risks regarding chemical and physical stability.
- Open Access
- 20 February 2026
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 42 (8) , 6471-6478
Self-Assembly of a Therapeutic Peptide Surfactant: A Small-Angle X-ray Scattering Study
Amphiphilic compounds are important in many fields including pharmaceutical processes and development. Synthetic surfactants are often toxic to biological systems and frequently display poor biodegradability. Biosurfactants, such as lipopeptides and bile salts, on the other hand, can offer superior properties with regard to toxicity, biodegradability, and efficiency. Lipidated peptides are also gaining interest as therapeutic agents, as they can offer enhanced pharmacokinetic properties, compared with native peptides. The amphiphilic nature of lipidated peptides suggests that they may self-assemble into micellar structures, which can influence formulation stability and biological performance. Understanding the aggregation behavior of lipidated peptides is thus important for identifying and avoiding stability issues that could affect drug efficacy and safety. Structural characterization of self-assembled aggregates provides insight into aggregation mechanisms, which is valuable for identifying potential challenges during the production, storage, and administration of pharmaceutical peptides. By using small-angle X-ray scattering (SAXS), we have investigated the size and morphology of aggregates formed by MEDI7219, a bis-lipidated glucagon-like peptide-1 (GLP-1) analogue, in various aqueous solutions. We demonstrate that the lipopeptide MEDI7219 behaves as a surfactant with high spontaneous curvature that forms small micelles with a clear core-and-shell structure in aqueous solvents. The aggregation numbers of the micelles vary in the range of 5-8 and are found to be surprisingly insensitive to environmental conditions such as type of electrolyte and tonicity modifier, different buffers, and temperature, while exhibiting very low critical micelle concentrations (cmc).
- 20 February 2026
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 42 (8) , 6471-6478
Open AccessSelf-Assembly of a Therapeutic Peptide Surfactant: A Small-Angle X-ray Scattering Study
Amphiphilic compounds are important in many fields including pharmaceutical processes and development. Synthetic surfactants are often toxic to biological systems and frequently display poor biodegradability. Biosurfactants, such as lipopeptides and bile salts, on the other hand, can offer superior properties with regard to toxicity, biodegradability, and efficiency. Lipidated peptides are also gaining interest as therapeutic agents, as they can offer enhanced pharmacokinetic properties, compared with native peptides. The amphiphilic nature of lipidated peptides suggests that they may self-assemble into micellar structures, which can influence formulation stability and biological performance. Understanding the aggregation behavior of lipidated peptides is thus important for identifying and avoiding stability issues that could affect drug efficacy and safety. Structural characterization of self-assembled aggregates provides insight into aggregation mechanisms, which is valuable for identifying potential challenges during the production, storage, and administration of pharmaceutical peptides. By using small-angle X-ray scattering (SAXS), we have investigated the size and morphology of aggregates formed by MEDI7219, a bis-lipidated glucagon-like peptide-1 (GLP-1) analogue, in various aqueous solutions. We demonstrate that the lipopeptide MEDI7219 behaves as a surfactant with high spontaneous curvature that forms small micelles with a clear core-and-shell structure in aqueous solvents. The aggregation numbers of the micelles vary in the range of 5-8 and are found to be surprisingly insensitive to environmental conditions such as type of electrolyte and tonicity modifier, different buffers, and temperature, while exhibiting very low critical micelle concentrations (cmc).
- 14 September 2024
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 77 (5) , 635-644
Pharmacokinetics of nano- and microcrystal formulations of low solubility compounds after intramuscular injection to mice
The aim of this study was to investigate the pharmacokinetics (PK) of poorly soluble compounds when administered intramuscularly (i.m.) as crystalline particles of different sizes. Three uncharged compounds (griseofulvin, AZ’72, and AZ’07) with varying aqueous solubility were dosed to mice at 10 and 50 mg/kg as nano- and microparticle formulations. The PK of the compounds was evaluated. The smaller particles of the drugs resulted in higher maximum plasma concentration (Cmax) and area under the plasma concentration–time profile (AUC) at 50 mg/kg. There was a dose-proportional increase in AUC but less than dose dose-proportional increase in Cmax. The evaluation at 10 mg/kg was more complex as increased exposure for nanoparticles was only observed for griseofulvin which has the highest solubility. In addition, there was an increase in half-life with an increase in dose. This study highlights that general expectations based on in vitro dissolution (i.e. that smaller particles dissolve faster than larger particles when surrounded by liquid) do not always translate to in vivo and demonstrates the importance of understanding the physicochemical properties of the drug, the characteristics of the formulations and the microphysiology at the delivery site.
- 14 September 2024
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 77 (5) , 635-644
Pharmacokinetics of nano- and microcrystal formulations of low solubility compounds after intramuscular injection to mice
The aim of this study was to investigate the pharmacokinetics (PK) of poorly soluble compounds when administered intramuscularly (i.m.) as crystalline particles of different sizes. Three uncharged compounds (griseofulvin, AZ’72, and AZ’07) with varying aqueous solubility were dosed to mice at 10 and 50 mg/kg as nano- and microparticle formulations. The PK of the compounds was evaluated. The smaller particles of the drugs resulted in higher maximum plasma concentration (Cmax) and area under the plasma concentration–time profile (AUC) at 50 mg/kg. There was a dose-proportional increase in AUC but less than dose dose-proportional increase in Cmax. The evaluation at 10 mg/kg was more complex as increased exposure for nanoparticles was only observed for griseofulvin which has the highest solubility. In addition, there was an increase in half-life with an increase in dose. This study highlights that general expectations based on in vitro dissolution (i.e. that smaller particles dissolve faster than larger particles when surrounded by liquid) do not always translate to in vivo and demonstrates the importance of understanding the physicochemical properties of the drug, the characteristics of the formulations and the microphysiology at the delivery site.
- 23 July 2024
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 77 (5) , 645-657
Case study: cremophor EL-based liquid formulations as simple substitutes for amorphous solid dispersions in early preclinical in vivo studies
The objective of the present case study was to increase the exposure of the poorly soluble crystalline compound A. Mice received 10 mg/kg of crystalline compound A formulated in eight different cosolvent, oil, and cyclodextrin mixtures. In all cases, AUC0–24h and maximum blood/plasma concentration (Cmax) were in the range of 6–16 µM × h and 0–24h and Cmax increased ~5–10 times. The obtained pharmacokinetic profile of the most improved formulation using CrEL was possible to superimpose on the one obtained after administration of a CrEL-free amorphous solid dispersion (ASD, HPMC-AS:drug, 80:20) suspension of compound A. It is crucial to find an optimal screen vehicle as early as possible for a poorly water-soluble lead series and then avoid time and resource-consuming vehicle testing of multiple compounds in vivo. An ASD approach is more suited for clinical development when more time and resources are allocated to the project. In this case study, some preclinical formulations were used to maximize exposure but also as preindicators for ASDs later in the development chain.
- 23 July 2024
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 77 (5) , 645-657
Case study: cremophor EL-based liquid formulations as simple substitutes for amorphous solid dispersions in early preclinical in vivo studies
The objective of the present case study was to increase the exposure of the poorly soluble crystalline compound A. Mice received 10 mg/kg of crystalline compound A formulated in eight different cosolvent, oil, and cyclodextrin mixtures. In all cases, AUC0–24h and maximum blood/plasma concentration (Cmax) were in the range of 6–16 µM × h and 0–24h and Cmax increased ~5–10 times. The obtained pharmacokinetic profile of the most improved formulation using CrEL was possible to superimpose on the one obtained after administration of a CrEL-free amorphous solid dispersion (ASD, HPMC-AS:drug, 80:20) suspension of compound A. It is crucial to find an optimal screen vehicle as early as possible for a poorly water-soluble lead series and then avoid time and resource-consuming vehicle testing of multiple compounds in vivo. An ASD approach is more suited for clinical development when more time and resources are allocated to the project. In this case study, some preclinical formulations were used to maximize exposure but also as preindicators for ASDs later in the development chain.
- 13 December 2023
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (24) , 24725-24742
The In Vivo Fate of Polycatecholamine Coated Nanoparticles Is Determined by a Fibrinogen Enriched Protein Corona
Polycatecholamine coatings have attracted significant attention in the past 10 years owing to their ability to functionalize a wide range of materials. Here we apply the use of such coatings to drug nanocrystals, made from a poorly soluble drug compound, to postfunctionalize the nanocrystal surface with the aim of providing steric stabilization and extending their circulation time after intravenous injection. We show that both polydopamine and polynorepinephrine can be used to successfully modify drug nanocrystals and subsequently incorporate end-functionalized PEG to the surface. Even though high grafting densities of PEG were achieved, we observed rapid clearance and increased liver uptake for polycatecholamine functionalized drug nanocrystals. Using both surface sensitive model systems and protein corona profiling, we determine that the rapid clearance was correlated with an increase in adsorption of proteins involved in coagulation to the polycatecholamine surface, with fibrinogen being the most abundant. Further analysis of the most abundant proteins revealed a significant increase in thiol-rich proteins on polycatecholamine coated surfaces. The observed interaction with coagulation proteins highlights one of the current challenges using polycatecholamines for drug delivery but might also provide insights to the growing use of these materials in hemostatic applications.
- 13 December 2023
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (24) , 24725-24742
The In Vivo Fate of Polycatecholamine Coated Nanoparticles Is Determined by a Fibrinogen Enriched Protein Corona
Polycatecholamine coatings have attracted significant attention in the past 10 years owing to their ability to functionalize a wide range of materials. Here we apply the use of such coatings to drug nanocrystals, made from a poorly soluble drug compound, to postfunctionalize the nanocrystal surface with the aim of providing steric stabilization and extending their circulation time after intravenous injection. We show that both polydopamine and polynorepinephrine can be used to successfully modify drug nanocrystals and subsequently incorporate end-functionalized PEG to the surface. Even though high grafting densities of PEG were achieved, we observed rapid clearance and increased liver uptake for polycatecholamine functionalized drug nanocrystals. Using both surface sensitive model systems and protein corona profiling, we determine that the rapid clearance was correlated with an increase in adsorption of proteins involved in coagulation to the polycatecholamine surface, with fibrinogen being the most abundant. Further analysis of the most abundant proteins revealed a significant increase in thiol-rich proteins on polycatecholamine coated surfaces. The observed interaction with coagulation proteins highlights one of the current challenges using polycatecholamines for drug delivery but might also provide insights to the growing use of these materials in hemostatic applications.
- 1 September 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 606, 120883
Supersaturated formulations of poorly soluble weak acid drugs evaluated in rodents; a case study
- 1 September 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 606, 120883
Supersaturated formulations of poorly soluble weak acid drugs evaluated in rodents; a case study
- 1 July 2019
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 45 (9) , 1477-1486
Nano- and microcrystals of griseofulvin subcutaneously administered to rats resulted in improved bioavailability and sustained release
Griseofulvin is a commonly used antifungal agent which is administered per oral (p.o.). The oral administration route, however, shows rather low bioavailability. The aim of this study was to improve the bioavailability and to evaluate and interpret the pharmacokinetic profiles after subcutaneous (s.c.) administration of crystalline griseofulvin nano- and microsuspensions. Both formulations were injected at 5 and 500 µmol/kg to rats. For the lower concentration, the profiles were similar after s.c. injection but extended as compared to p.o. administration. For the higher concentration, injection of microsuspension resulted in a maintained plateau whereas the nanosuspension resulted in an obvious peak exposure followed by extended elimination. Both suspensions showed improved exposure with dose. The differences in peak exposures between nano- and microparticles, at the high dose, were mainly ascribed to differences in dissolution rate, experimentally determined in vitro, using spectroscopic methods. The extended appearance in the circulation may depend on the physicochemical properties of the compound and the physiological conditions at the injection site. The bioavailability was improved for both formulations compared with an orally administered nanosuspension, suggesting the s.c. route to be a preferred administration option for compounds with low oral bioavailability regarding both overall exposure and extended efficacy.
- 1 July 2019
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 45 (9) , 1477-1486
Nano- and microcrystals of griseofulvin subcutaneously administered to rats resulted in improved bioavailability and sustained release
Griseofulvin is a commonly used antifungal agent which is administered per oral (p.o.). The oral administration route, however, shows rather low bioavailability. The aim of this study was to improve the bioavailability and to evaluate and interpret the pharmacokinetic profiles after subcutaneous (s.c.) administration of crystalline griseofulvin nano- and microsuspensions. Both formulations were injected at 5 and 500 µmol/kg to rats. For the lower concentration, the profiles were similar after s.c. injection but extended as compared to p.o. administration. For the higher concentration, injection of microsuspension resulted in a maintained plateau whereas the nanosuspension resulted in an obvious peak exposure followed by extended elimination. Both suspensions showed improved exposure with dose. The differences in peak exposures between nano- and microparticles, at the high dose, were mainly ascribed to differences in dissolution rate, experimentally determined in vitro, using spectroscopic methods. The extended appearance in the circulation may depend on the physicochemical properties of the compound and the physiological conditions at the injection site. The bioavailability was improved for both formulations compared with an orally administered nanosuspension, suggesting the s.c. route to be a preferred administration option for compounds with low oral bioavailability regarding both overall exposure and extended efficacy.
- 1 July 2019
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 566, 565-572
Sustained release and improved bioavailability in mice after subcutaneous administration of griseofulvin as nano- and microcrystals
- 1 July 2019
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 566, 565-572
Sustained release and improved bioavailability in mice after subcutaneous administration of griseofulvin as nano- and microcrystals
- 29 November 2018
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 128, 128-136
The crystalline salt form of a selected candidate drug showed photo-, thermal- and humidity induced form transitions
- 29 November 2018
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 128, 128-136
The crystalline salt form of a selected candidate drug showed photo-, thermal- and humidity induced form transitions